SCHEMBL20674151

SCHEMBL20674151

O=C(CO)c1nc(O)n2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.38
▸ KDM4E B2RXH2 4/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CNR2 P34972 3/20 0.37
▸ PTGS1 P23219 2/20 0.36
▸ PTGS2 P35354 2/20 0.36
▸ GAA P10253 2/20 0.36
▸ GUCY1A1 Q02108 1/20 0.36
▸ GUCY1B1 Q02153 1/20 0.36
▸ BAZ2B Q9UIF8 3/20 0.35
▸ BAZ2A Q9UIF9 3/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ BRD9 Q9H8M2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20674161 0.80 MAP2K3 (0.46) ALDH1A1KDM4EL3MBTL1MEN1MAPT
SCHEMBL20674150 0.80 BAZ2B (0.46) ALDH1A1KDM4EL3MBTL1MEN1MAPT
SCHEMBL20674510 0.76 CNR2 (0.44) ALDH1A1KDM4EKMT2ACNR2GAA
SCHEMBL20674628 0.74 MAP2K3 (0.40) ALDH1A1KDM4EL3MBTL1MEN1MAPT
SCHEMBL20674156 0.73 HIF1A (0.43) ALDH1A1KDM4EL3MBTL1MEN1MAPT
SCHEMBL20674504 0.68 PTPN1 (0.56) ALDH1A1KDM4EL3MBTL1MEN1MAPT
SCHEMBL20674505 0.68 ALDH1A1 (0.56) ALDH1A1KDM4EL3MBTL1MEN1MAPT
SCHEMBL20673874 0.68 USP7 (0.53) ALDH1A1KDM4EL3MBTL1MEN1MAPT
SCHEMBL20673884 0.65 USP7 (0.48) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL20674500 0.65 KDM4E (0.43) ALDH1A1KDM4EL3MBTL1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 ALDH1A1 3193/4885KDM4E 1867/4885L3MBTL1 324/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 ALDH1A1 3193/4885KDM4E 1867/4885L3MBTL1 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback